Skip to main content
Signal8
Launch Terminal

MediWound Ltd. (MDWD)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Sector: Medicinal Chemicals & Botanical Products

Industry: Biotechnology

MediWound Ltd. logo

MediWound Ltd.

NASDAQ:MDWDHealthcare
-4.04%$13.30
AH$13.30+0.00%vs close
Mkt Cap$172.89M
Float11.36M
O/S13M
Vol
$ Vol
RVOL
Inst Own44.8%
SI15.4%
Earnings
Dilution
MediWound Ltd. logoNASDAQ:MDWD$13.30-4.04%
Phase Distribution
15 lead-sponsored trials·2 active·8 completed
Phase 1/21
Phase 27
Phase 34
Not applicable3
Status Overview
Not yet recruiting2
Recruiting2
Completed8
Stopped1
Expanded access1
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Completed

    Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care

    DGD

    Burn

    Enrollment
    182
    Start
    Dec 2005
    Primary Completion
    Oct 2009
    Completion
    Feb 2010
    NCT00324311
  • Phase 3
    Completed

    A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns

    NexoBrid, Gel Vehicle

    Thermal Burns

    Enrollment
    175
    Start
    May 2015
    Primary Completion
    Jun 2018
    Completion
    Aug 2020
    NCT02148705
  • Phase 3
    Completed

    A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care

    NexoBrid

    Thermal Burns

    Enrollment
    145
    Start
    May 2015
    Primary Completion
    Apr 2021
    Completion
    Dec 2022
    NCT02278718
  • Phase 3
    Recruiting

    A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

    EscharEx (EX-03), Placebo (Gel vehicle)

    Venous Leg Ulcer (VLU)

    Enrollment
    216
    Start
    Jun 2025
    Primary Completion
    Dec 2026est.
    Completion
    Mar 2027est.
    NCT06568627
  • Phase 2
    Completed

    Feasibility Study: Enzymatic Debridement in Patients With Partial Thickness Burns

    DGD

    Burn

    Enrollment
    36
    Start
    Dec 2009
    Primary Completion
    Dec 2015
    Completion
    Dec 2015
    NCT00898521
  • Phase 2
    Terminated

    A Study, Performed in Subjects With Post Traumatic-post Surgical ,Venus Insufficiency and Diabetic Hard to Heal/Chronic Wounds, to Evaluate the Safety and Efficacy of PolyHeal-2 Versus PolyHeal in Once Daily Regimen

    PolyHeal 2, Polyheal

    Surgical Wound Dehiscence

    Enrollment
    15
    Start
    Nov 2012
    Primary Completion
    Aug 2014
    Completion
    Aug 2014
    NCT01679678
  • Phase 2
    Completed

    Efficacy and Safety Study of EscharEx to Treat (Debride) Hard to Heal Wounds

    EscharEx, Gel Vehicle

    Hard to Heal Wounds, Venous Leg Ulcers +2

    Enrollment
    111
    Start
    Jul 2014
    Primary Completion
    Dec 2017
    Completion
    Jun 2018
    NCT02020746
  • Phase 2
    Completed

    A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

    EscharEx (5% EX-02 formulation), Gel Vehicle

    Venous Leg Ulcer

    Enrollment
    120
    Start
    Dec 2019
    Primary Completion
    Dec 2021
    Completion
    Mar 2022
    NCT03588130
  • Phase 2
    Completed

    A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers

    EscharEx (EX-02 formulation)

    Venous Leg Ulcer, Diabetic Foot Ulcer

    Enrollment
    12
    Start
    Apr 2021
    Primary Completion
    May 2022
    Completion
    May 2022
    NCT04817228
  • Phase 2
    Not yet recruiting

    Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)

    EscharEx (EX-03), Placebo (Gel vehicle)

    Venus Leg Ulcers

    Enrollment
    45
    Start
    Jan 2027est.
    Primary Completion
    Nov 2028est.
    Completion
    Jan 2029est.
    NCT06690177
  • Phase 2
    Not yet recruiting

    An Open Label, Single Treatment, Single Arm, Multiple Dose Phase-2 Study to Evaluate the Pharmacokinetics, Safety, and Clinical Performance of EscharEx (EX-03) in Participants With Venous Leg Ulcers

    EX-03

    Venous Leg Ulcer (VLU)

    Enrollment
    20
    Start
    Aug 2026est.
    Primary Completion
    Aug 2028est.
    Completion
    Aug 2028est.
    NCT07692178
  • Phase 1/2
    Recruiting

    A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma

    EscharEx 5% (EX-02 formulation)

    Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma

    Enrollment
    32
    Start
    Jun 2021
    Primary Completion
    May 2022est.
    Completion
    Jun 2022est.
    NCT05157763
  • Observational
    Completed

    Long Term Follow up of Scars Formation and Quality of Life Assessment Study

    Scars assessment & QOL

    Scars Formation, Quality of Life

    Enrollment
    148
    Start
    Jun 2011
    Primary Completion
    Nov 2011
    Completion
    Nov 2011
    NCT01350700
  • Observational
    Unknown status

    Functionality Assessments in Patients (Adults and Children) Following Treatment With Debrase Compared to Standard of Care

    -

    Burns, Upper Extremity, Burns, Lower Extremity

    Enrollment
    53
    Start
    Mar 2013
    Primary Completion
    Jul 2013est.
    Completion
    -
    NCT01800981
  • Expanded access
    Approved for marketing

    Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries

    NexoBrid

    Thermal Burn

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT04040660
Search ClinicalTrials.gov for “MediWound”